Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Aksoy

Showing results (141-150 of 206) with videos related to

Pageof 21
Sort By:
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|September 28, 2014
Impact of inflammatory markers on the prognosis of patients with operable breast cancerIbrahim Petekkaya, Sercan Aksoy, Emir C Roach, et al.
Journal of Clinical Medicine|August 12, 2022
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with ImmunotherapyDeniz Can Guven, Taha Koray Sahin, Enes Erul, et al.
Hepato-Gastroenterology|April 27, 2012
XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancerVeli Berk, Nuriye Ozdemir, Metin Ozkan, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 27, 2014
Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumorsTarkan Yetisyigit, Nalan Babacan, Yuksel Urun, et al.
Irish Journal of Medical Science|September 2, 2021
THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapyOktay Halit Aktepe, Fatma Gundogdu, Kemal Kosemehmetoglu, et al.
Nature Communications|November 2, 2023
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancerOzge Saatci, Metin Cetin, Meral Uner, et al.
Cell Death and Differentiation|March 2, 2023
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplificationOzge Saatci, Ozge Akbulut, Metin Cetin, et al.
Future Oncology (London, England)|April 13, 2019
The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetateCem Onal, Ali Murat Sedef, Fatih Kose, et al.
Immunotherapy|June 5, 2025
Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitorsOnur Bas, Mert Tokatlı, Naciye Guduk, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 1, 2019
Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetateBerna Akkus Yildirim, Cem Onal, Fatih Kose, et al.
Pageof 21

Showing results (141-150 of 206) with videos related to

Sort By:
Pageof 21
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|September 28, 2014
Impact of inflammatory markers on the prognosis of patients with operable breast cancerIbrahim Petekkaya, Sercan Aksoy, Emir C Roach, et al.
Journal of Clinical Medicine|August 12, 2022
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with ImmunotherapyDeniz Can Guven, Taha Koray Sahin, Enes Erul, et al.
Hepato-Gastroenterology|April 27, 2012
XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancerVeli Berk, Nuriye Ozdemir, Metin Ozkan, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 27, 2014
Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumorsTarkan Yetisyigit, Nalan Babacan, Yuksel Urun, et al.
Irish Journal of Medical Science|September 2, 2021
THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapyOktay Halit Aktepe, Fatma Gundogdu, Kemal Kosemehmetoglu, et al.
Nature Communications|November 2, 2023
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancerOzge Saatci, Metin Cetin, Meral Uner, et al.
Cell Death and Differentiation|March 2, 2023
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplificationOzge Saatci, Ozge Akbulut, Metin Cetin, et al.
Future Oncology (London, England)|April 13, 2019
The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetateCem Onal, Ali Murat Sedef, Fatih Kose, et al.
Immunotherapy|June 5, 2025
Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitorsOnur Bas, Mert Tokatlı, Naciye Guduk, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 1, 2019
Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetateBerna Akkus Yildirim, Cem Onal, Fatih Kose, et al.
Pageof 21